



# Pharmacology

---

## **H. P. Rang**

MB BS MA DPhil FRS

Director, Sandoz Institute for Medical Research;  
Visiting Professor of Pharmacology, University College, London

## **M. M. Dale**

MB BCh PhD

Senior Lecturer, Department of Pharmacology,  
University College, London



**CHURCHILL LIVINGSTONE**

**EDINBURGH LONDON MELBOURNE AND NEW YORK 1987**

CHURCHILL LIVINGSTONE  
Medical Division of Longman Group UK Limited

Distributed in the United States of America by Churchill Livingstone Inc., 1560 Broadway, New York, N.Y. 10036, and by associated companies, branches and representatives throughout the world.

© Longman Group UK Limited 1987

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publishers (Churchill Livingstone, Robert Stevenson House, 1-3 Baxter's Place, Leith Walk, Edinburgh EH1 2AF).

First published 1987

ISBN 0-443-03407-9

**British Library Cataloguing in Publication Data**

Rang, H. P.  
Pharmacology.  
I. Pharmacology  
I. Title II. Dale, M. Maureen.  
615'.1 RM300

**Library of Congress Cataloging in Publication Data**

Rang, H. P.  
Pharmacology.  
Includes index.  
I. Pharmacology. I. Dale, M. Maureen. II. Title.  
[DNLM: 1. Pharmacology. QV 4 R196p]  
RM300.R35 1986 615'.1 86-12914

## Preface

This book is intended primarily for preclinical medical students and science students studying pharmacology, but clinicians who wish to brush up their basic science and scientists in other disciplines who want to get an overall grasp of pharmacology may find it useful.

It is the successor to '*Applied Pharmacology*' by H O Schild and has developed out of it. Both authors were students under Heinz Schild and in writing the present book we have had very much in mind his approach to pharmacology. However, because of the developments in the subject and in the biological sciences in general, we felt it apposite not just to update his text but to rewrite it. We have reduced somewhat the element of clinical pharmacology in view of the fact that this material is best dealt with when students have had some experience of clinical medicine and because there are now many excellent textbooks on clinical pharmacology. Consequently we have abandoned the title '*Applied Pharmacology*' in favour of '*Pharmacology*', the subject being defined as 'the study of the effects of chemical substances on living tissue'. Inherent in this definition is the fact that pharmacology is not synonymous with clinical pharmacology; it provides the clinician with the agents used in therapeutics and with the understanding of how they work, but it is concerned not only with drugs used in treatment but also with drugs used as investigatory tools. With this definition in mind we have concentrated on pharmacodynamics and pharmacokinetics, and in the context of the former we have stressed mechanisms of action, believing that if an individual understands more of how a drug works he or she will use it more intelligently in the clinic or laboratory. In addition to dealing with drugs as such, we have placed emphasis on

'mediators', since understanding the body's method of controlling its own functions is a route not only to the understanding of how exogenous chemical substances affect it but also to the rational development of new drugs. Descriptions of peripheral neurotransmitters such as acetylcholine and nor-adrenaline, of hormones such as hydrocortisone, and of inflammatory mediators such as histamine, have always formed part of pharmacology textbooks and it is well known that investigation of the actions and structure/activity relationships of these substances has led to the development of valuable drugs for the clinician. We have carried this approach a little further, with an eye on future developments. Thus, in the sections on the central nervous system we have included discussions of various CNS neurotransmitters and neuromodulators (GABA, glutamate, neuropeptides, etc), and their possible significance in some clinical disorders, even though useful drugs that are known to act by affecting the metabolism or actions of these mediators have yet to emerge. Similarly we have included brief descriptions of inflammatory mediators such as platelet activating factor and interleukin-1 and their possible role in conditions such as asthma and rheumatoid arthritis. Drugs used in inflammation and as immunosuppressives form an important part of the therapeutic armamentarium and an appreciation of how they act and how new drugs in this area are likely to be developed requires some knowledge of what happens in inflammation. Since pathology and immunology generally come later in the medical course than pharmacology, and since pharmacology students generally do not study these subjects at all, we have included a brief outline of the main events in the inflammatory and immune responses.

While making it clear that any mistakes in the book are our own, we would like to acknowledge help and advice from the following people: Dr J G Blackman, Dr D G Haylett, Isobel Heyman, Dr D M James, Dr I F James, Prof. J Mandelstam, Dr R Pitt-Rivers and Dr G Robinson. In particular we wish to acknowledge the invaluable help of Janet

Martin, who drew all the diagrams and Marie-Claire Stuart, Annabel Giles and Joyce Mancini who prepared the text.

London  
1987

H P Rang  
M M Dale

# Contents

## SECTION ONE: GENERAL PRINCIPLES

<b>1: Mechanisms of drug action</b>	<b>3</b>	Therapeutic index	48
Systems of medicine	3	Chemical assay methods	50
The binding of drug molecules to cells	4	Radioimmunoassay	50
Receptor classification	6	Chromatographic techniques	51
Note on terminology	6	Mass spectrometry	53
Quantitative aspects	7	Spectrophotometry and fluorimetry	55
Agonist dose-response curves	8	<b>3: Absorption, distribution and fate of drugs</b>	<b>57</b>
Competitive antagonism	9	Translocation of drug molecules	57
Partial agonists and the concept of efficacy	10	Movement of drug molecules across cellular barriers	58
Direct measurement of drug binding to receptors	12	Diffusion through lipid	58
Isolation and characterization of receptor molecules	14	Carrier-mediated transport	62
Receptor-effector linkage	16	Partition into body fat	62
Direct regulation of ionic permeability	16	Binding of drugs to plasma proteins	63
Mechanisms involving a second messenger	19	Phases of drug disposition	65
Regulation of DNA transcription	27	Drug absorption	66
Types of drug antagonism	28	Absorption from the alimentary canal	66
Chemical antagonism	28	Sublingual administration	66
Pharmacokinetic antagonism	28	Oral administration	66
Antagonism by receptor block	28	Bioavailability	68
Physiological antagonism	31	Other routes of administration	69
Desensitization and tachyphylaxis	34	Rectal administration	69
Definition of terms	33	Cutaneous administration	69
		Eye-drops	69
		Administration by inhalation	70
		Administration by injection	70
		Distribution of drugs in the body	71
		Body fluid compartments	71
		Volume of distribution	72
		Removal of drugs from the body	72
		Drug metabolism	73
		Phase I reactions	74
		Phase II reactions	76
		Induction of microsomal enzymes	77
		First-pass metabolism	77
		Pharmacologically active drug metabolites	78
<b>2: Measurement in pharmacology</b>	<b>35</b>		
Bioassay	35		
General principles of bioassay	37		
Use of standards	37		
Design of bioassays	38		
Quantal and graded responses	41		
Bioassays in man	42		
Clinical trials	43		
Measurement of toxicity	46		

Renal excretion of drugs and drug metabolites	78	Electrical events in transmission	116
Glomerular filtration	78	Depolarization block	117
Tubular secretion and reabsorption	78	Effects of drugs on cholinergic transmission	118
Diffusion across the renal tubule	79	Muscarinic agonists	119
Drug excretion expressed as clearance	79	Muscarinic antagonists	121
Biliary excretion and enterohepatic circulation	81	Ganglion stimulating drugs	124
Pharmacokinetics	81	Ganglion blocking drugs	125
Single compartment model	81	Neuromuscular blocking drugs	129
More complicated kinetic models	86	Drugs affecting acetylcholine synthesis	129
Two compartment model	86	Drugs that inhibit acetylcholine release	130
Saturation kinetics	87	Drugs that enhance cholinergic transmission	137
Special drug delivery systems	89	Distribution and function of cholinesterase	137
<b>4: Individual variation and drug interactions</b>	<b>90</b>	Drugs that inhibit cholinesterase	138
Effects of age	90	Cholinesterase reactivation	142
Genetic factors	92	Myasthenia gravis	143
Drug interactions	94	Other drugs which enhance transmission	144
Pharmacodynamic interaction	94	<b>7: Adrenergic transmission</b>	<b>146</b>
Pharmacokinetic interaction	95	Classification of adrenergic receptors	146
Absorption phase	95	Physiology of adrenergic transmission	148
Effects on drug distribution	96	The adrenergic neuron	148
Effects on drug metabolism	96	Noradrenaline synthesis	150
Haemodynamic effects	97	Noradrenaline storage	151
Effects on drug excretion	97	Noradrenaline release	151
		Uptake and degradation of catecholamines	153
<b>SECTION TWO: CHEMICAL MEDIATORS</b>		Drugs acting on adrenoceptors	156
<b>5: Chemical transmission and the autonomic nervous system</b>	<b>101</b>	Structure-activity relationships	156
Basic anatomy and physiology of the autonomic nervous system	103	Adrenoceptor agonists	158
General principles of chemical transmission	106	Adrenoceptor blocking agents	161
Denervation supersensitivity	106	$\alpha$ -receptor antagonists	161
Dale's principle	106	$\beta$ -receptor antagonists	167
Recent developments	107	Drugs that affect adrenergic neurons	169
Presynaptic interactions	108	Drugs that affect noradrenaline synthesis	170
Transmitters other than acetylcholine and noradrenaline	110	Drugs that affect noradrenaline storage	170
Basic steps in neurochemical transmission—sites of drug action	111	Drugs that affect noradrenaline release	170
<b>6: Cholinergic transmission</b>	<b>113</b>	Adrenergic neuron blocking drugs	171
Muscarinic and nicotinic actions of acetylcholine	113	Indirectly-acting sympathomimetic amines	172
Acetylcholine receptors	114	Drugs that affect presynaptic receptors	173
Physiology of cholinergic transmission	115	Inhibitors of noradrenaline uptake	174
Acetylcholine synthesis and release	116	Definition of terms	175
		<b>8: Local hormones, inflammation and allergy</b>	<b>177</b>
		The inflammatory reaction and the immune response	178
		Vascular events	178

Cellular events	181	Organic nitrates	250
The significance of the specific immunological response	182	Dipyridamole	254
Mediators of inflammation and allergy	187	Other drugs that affect the heart	254
Histamine	187	Methylxanthines	254
Eicosanoids	192	Purines	254
Bradykinin	198	Other agents	255
Platelet activating factor (PAF)	201	<b>11: The circulation</b>	<b>256</b>
Interleukin-1	203	Vascular smooth muscle	256
$\gamma$ -Interferon	203	Vasoconstrictor drugs	258
<b>9: Drugs used to suppress inflammatory and immune reactions</b>	<b>204</b>	Sympathomimetic amines	258
Non-steroidal anti-inflammatory drugs (NSAIDs)	204	Angiotensin	259
Pharmacological actions	204	Vasopressin (Antidiuretic hormone)	259
Mechanism of action of NSAIDs	207	Vasodilator drugs	260
Anti-rheumatoid drugs	213	Nitroprusside	260
Drugs used in gout	216	Hydrallazine	260
Antagonists of histamine	218	Diazoxide	261
Immunosuppressants	221	Papaverine	261
<b>SECTION THREE: DRUGS AFFECTING MAJOR ORGAN SYSTEMS</b>		Endogenous mediators	261
<b>10: The heart</b>	<b>227</b>	Serotonin	261
Physiology of cardiac function	227	Purines	265
Cardiac rate and rhythm	227	Dopamine	266
Disturbances of cardiac rhythm	229	Atrial peptides	268
Cardiac contraction	231	Vasodilator drugs that act indirectly	269
Myocardial oxygen consumption and coronary blood flow	234	The renin-angiotensin system	269
Coronary atherosclerosis and its consequences	235	Angiotensin converting-enzyme inhibitors	270
Drugs that affect cardiac function	236	Angiotensin antagonists	270
Autonomic transmitters and related drugs	236	Clinical use of vasodilator drugs	272
Cardiac glycosides	239	Hypertension	272
Chemistry	239	Cardiac failure	273
Pharmacological actions	239	Shock and hypotensive states	273
Effects on the heart in normal and pathological states	240	Migraine	275
Pharmacokinetic aspects	243	<b>12: Haemostasis and thrombosis</b>	<b>281</b>
Adverse effects	244	Blood coagulation	281
Antidysrhythmic drugs	244	Coagulation defects	283
Class I antidysrhythmic drugs	245	Vitamin K	283
Class II antidysrhythmic drugs	247	Unwanted coagulation	285
Class III antidysrhythmic drugs	247	Oral anticoagulants	286
Class IV antidysrhythmic drugs	248	Injectable anticoagulants	287
Anti-anginal drugs	250	Platelet adhesion and activation	289
		Platelets and arachidonate metabolites	292
		Antiplatelet agents	293
		Fibrinolysis	294
		Fibrinolytic drugs	294
		Antifibrinolytic drugs	295
		Therapeutic uses of anticoagulants, anti-platelet agents and fibrinolytic drugs	295
		Venous thromboembolism	295



Arterial thromboembolism	295	H <sub>2</sub> -receptor antagonists	336
Miscellaneous conditions	296	Anticholinergic agents	337
<b>13: The respiratory system</b>	<b>297</b>	Antacids	338
The regulation of respiration	297	Drugs which promote the healing of ulcers	339
Drugs which affect respiration	298	Vomiting	339
Respiratory stimulants	298	Emetic drugs	342
Drugs causing respiratory depression	299	Anti-emetic drugs	342
Functions of the lung unrelated to respiration	299	The motility of the gastro-intestinal tract	346
The regulation of the musculature, blood vessels and glands of the airways	299	Purgatives	347
Disorders of respiratory function	301	Drugs which increase gastro-intestinal motility	349
Drugs used to treat asthma	304	Antidiarrhoeal drugs	350
Drugs used for cough	307	Pharmacology of bile	352
<b>14: The kidney</b>	<b>309</b>	<b>16: The endocrine system</b>	<b>358</b>
The structure and function of the nephron	309	The pituitary	358
The control of extracellular fluid osmolarity	315	The anterior pituitary (adenohypophysis)	358
Concentrating mechanisms: the counter-current multiplier system in the medulla	315	Hypothalamic hormones	359
Acid-base balance	316	Growth hormone-releasing factor (GHRF)	359
Potassium balance	317	Somatostatin	361
Excretion of organic molecules	318	Thyrotropic-releasing hormone (protirelin; TRH)	361
Arachidonic acid metabolites and renal function	318	Corticotrophin-releasing factor (CRF)	362
Drugs acting on the kidney	318	Gonadotrophin-releasing factor	362
Diuretics	318	Anterior pituitary hormones	362
The development of diuretic drugs	319	Growth hormone	362
Diuretics acting directly on the cells of the nephron	321	Prolactin	363
Diuretics acting indirectly by modify- ing the content of the filtrate	325	Corticotrophin	366
Obsolete or near obsolete diuretics	326	Melanocyte-stimulating hormones (MSH)	366
General aspects of the action of diuretics	326	Gonadotrophic hormones	366
Drugs which alter the pH of the urine	327	Posterior pituitary (neurohypophysis)	366
Drugs which alter the excretion of organic molecules	328	Antidiuretic hormone (ADH)	367
<b>15: The gastrointestinal tract</b>	<b>330</b>	Oxytocin	369
The innervation and hormones of the gastrointestinal tract; gastric secretion; the regulation of acid secretion	330	Thyroid	369
Drugs used in the diagnosis and treatment of gastric and duodenal disorders	335	Regulation of thyroid function	371
Stimulants of gastric acid secretion	336	Actions of thyroid hormones	373
		Abnormalities of thyroid function	374
		Drugs used in hyperthyroidism	375
		Drugs used in hypothyroidism	378
		The endocrine pancreas	378
		Insulin, glucagon, somatostatin and the control of blood glucose	379
		Diabetes mellitus and drugs used in the treatment of diabetes mellitus	386
		Insulin	388
		Oral hypoglycaemic agents	390

ACTH and the adrenal steroids	393	Central noradrenergic pathways	448
Glucocorticoids	394	Functional aspects	449
Corticotrophin	403	Dopamine	451
Mineralocorticoids	404	Dopamine pathways in the CNS	451
Parathyroid hormone, vitamin D, and bone mineral homeostasis	405	Dopamine receptors in the CNS	453
The structure of bone; calcium; phosphate and parathormone	405	Functional aspects	453
Vitamin D	408	Serotonin	455
Calcitonin	410	Central serotonin pathways	455
Other agents used in disorders of calcium and phosphate metabolism	410	Functional aspects	455
<b>17: The reproductive system</b>	<b>413</b>	Acetylcholine	457
Endocrine aspects	413	Central cholinergic pathways	458
Hormonal control of the female reproductive system	413	Functional aspects	459
The behavioural effects of sex hormones	415	Amino-acid transmitters	460
Oestrogens	415	GABA	461
Anti-oestrogens	419	Glycine	462
Progestogens	419	Excitatory amino-acids	463
Anti-progestogens	421	Neuropeptides	464
Hormonal control of the male reproductive system	421	Opioid peptides	466
Androgens	422	Purines	468
Anabolic steroids	423	Histamine	468
Anti-androgens	423	The classification of psychotropic drugs	469
Gonadotrophin releasing hormone	424	<b>20: General anaesthetic agents</b>	<b>471</b>
Gonadotrophins	424	Physicochemical theories of anaesthesia	472
Miscellaneous drugs affecting the reproductive system	424	Lipid theory	472
Drugs used for contraception	425	Hydrate theory	473
The uterus	426	Protein theory	473
The motility of the uterus; innervation and action of sympathomimetic amines; the role of posterior pituitary hormones	426	The effects of anaesthetics on the nervous system	474
Oxytocic drugs	428	Stages of anaesthesia	475
<b>18: The haemopoietic system</b>	<b>433</b>	Effects on the cardiovascular and respiratory systems	475
Types of anaemia	433	Inhalation anaesthetics—	
Iron	434	pharmacokinetic aspects	476
Vitamin B <sub>12</sub> and folic acid	437	The solubility of anaesthetics	476
Vitamin C	443	Induction and recovery	478
<b>SECTION FOUR: THE CENTRAL NERVOUS SYSTEM</b>		Metabolism of inhalation anaesthetics	480
<b>19: Chemical transmission and drug action in the central nervous system</b>	<b>447</b>	Individual inhalation anaesthetics	480
Individual neurotransmitters	448	Diethyl ether	481
Noradrenaline	448	Halothane	481
		Nitrous oxide	481
		Methoxyflurane	482
		Enflurane	482
		Intravenous anaesthetic agents	482
		Thiopentone	483
		Althesin	484
		Ketamine	485
		<b>21: Anxiolytic and hypnotic drugs</b>	<b>486</b>
		The measurement of anxiolytic activity	486

Tests on animals	486	Interactions with drugs and foods	524
Tests on humans	487	'Atypical antidepressants'	525
Classification of anxiolytic and hypnotic drugs	488	Electroconvulsive therapy (ECT)	526
Benzodiazepines	488	Clinical effectiveness of antidepressant treatments	526
Chemistry and structure-activity relationships	488	Lithium	528
Pharmacological effects	488	Pharmacological effects and mechanism of action	528
Mechanism of action	490	Pharmacokinetic aspects and toxicity	529
Benzodiazepine antagonists	491	<b>24: Drugs used in treating motor disorders: epilepsy, Parkinsonism and spasticity</b>	<b>530</b>
Pharmacokinetic aspects	493	Epilepsy	530
Adverse effects	494	Types of epilepsy	531
Other sedative and hypnotic drugs	496	Cellular mechanisms underlying epilepsy	531
Barbiturates	496	Mechanism of action of anticonvulsant drugs	533
Meprobamate	497	Individual drugs	535
Chloral hydrate and trichlorethanol	498	Phenytoin	535
Glutethimide and methaqualone	498	Phenobarbitone	536
<b>22: Neuroleptic drugs</b>	<b>499</b>	Primidone	537
The nature of schizophrenia	499	Ethosuximide	537
Theories of schizophrenia	499	Trimethadione	538
Neuroleptic drugs	502	Valproate	538
Chemical aspects	502	Carbamazepine	538
Mechanism of action	505	Benzodiazepines	539
Behavioural effects	506	Parkinsonism	539
Other effects related to dopamine antagonism	507	Levodopa	541
Actions unrelated to dopamine antagonism	508	Other drugs used in Parkinsonism	543
Side effects	509	Huntington's chorea	544
Pharmacokinetic aspects	509	Muscle spasm and centrally-acting muscle relaxants	544
Clinical uses and clinical efficacy	510	Mephenesin	545
<b>23: Drugs used in affective disorders</b>	<b>513</b>	Baclofen	545
The nature of affective disorders	513	<b>25: Analgesic drugs</b>	<b>547</b>
The monoamine theory of depression	513	Neutral mechanisms of pain sensation	547
Animal models of depression	516	Nociceptive afferent neurons	547
Antidepressant drugs	517	The substantia gelatinosa and the gate control theory	548
Types of antidepressant drug	517	Descending inhibitory controls	549
Measurement of antidepressant activity	517	Chemical mediators and the nociceptive pathway	550
Tricyclic antidepressants	518	Pain and nociception	553
Chemical aspects	518	Morphine-like drugs	553
Mechanism of action	519	Chemical aspects	554
Actions and side effects	520	Opioid receptors	555
Pharmacokinetic aspects	521	Cellular mechanism of action	557
Monoamine oxidase inhibitors (MAOI)	522	Pharmacological actions	558
Chemical aspects	522		
Pharmacological effects	523		
Side effects and toxicity	524		

Effects on the central nervous system	558	The formed structures of the cell and/or specialized cell types as potential targets	60
Effects on the gastrointestinal tract	560	Resistance to antibiotics	60
Other actions	560	Genetic determinants of antibiotic resistance	604
Tolerance and dependence	560	The transfer of resistance genes between genetic elements within the bacterium	605
Metabolism and pharmacokinetic aspects	563	The transfer of resistance genes between bacteria	605
Unwanted effects	563	Biochemical mechanisms of resistance to antibiotics	606
Other opioid analgesics	563		
Opioid antagonists	565		
<b>26: Central nervous system stimulants and psychotomimetic drugs</b>	<b>568</b>	<b>29: Cancer chemotherapy</b>	<b>608</b>
Convulsants and respiratory stimulants	568	General principles of action of anticancer drugs	609
Psychomotor stimulants	571	Drugs used in cancer chemotherapy	610
Amphetamines and related drugs	571	Alkylating agents	610
Pharmacological effects	571	Antimetabolites	614
Tolerance and dependence	573	Cytotoxic antibiotics	618
Pharmacokinetic aspects	573	Vinca alkaloids	619
Uses and unwanted effects	573	Cisplatin	619
Cocaine	573	Hormones	619
Methylxanthines	574	Radioactive isotopes	620
Pharmacological effects	574	Miscellaneous agents	620
Uses and unwanted effects	575	Drug resistance	620
Psychotomimetic drugs	575	Cell cycle: Drug effects and their possible clinical applications	621
LSD, psilocin and mescaline	576	Possible future strategies for cancer chemotherapy	622
Phencyclidine	577		
<b>27: Local anaesthetics and other drugs that affect excitable membranes</b>	<b>579</b>	<b>30: Antibacterial agents</b>	<b>626</b>
Na <sup>+</sup> and K <sup>+</sup> channels of excitable membranes	579	Sulphonamides	628
Drugs that affect Na <sup>+</sup> channels	582	Penicillin	631
Local anaesthetics	583	Cephalosporin and cephamycins	634
Chemical aspects	584	Tetracyclines	636
Mechanism of action	584	Chloramphenicol	637
Effects on other physiological systems	586	Aminoglycosides	638
Unwanted effects	587	Other antibiotics	640
Pharmacokinetic aspects	587	Antimycobacterial agents	643
Methods of administration	587	Drugs used to treat tuberculosis	643
Tetrodotoxin and saxitoxin	588	Drugs used to treat leprosy	645
Agents that affect Na <sup>+</sup> channel gating	589		
Agents that affect K <sup>+</sup> channels	590		
<b>SECTION FIVE: CHEMOTHERAPY</b>		<b>31: Antiviral drugs</b>	<b>647</b>
<b>28: Basic principles of chemotherapy</b>	<b>595</b>	Inhibition of attachment to or penetration of host cells	647
The molecular basis of chemotherapy	595	Inhibition of nucleic acid synthesis	648
Biochemical reactions as potential targets	597	Interferon	650

<b>32: Antifungal drugs</b>	<b>652</b>	<b>34: Anthelmintic drugs</b>	<b>669</b>
Amphotericin; Nystatin	653	Actions of anthelmintic drugs	670
Flucytosine	654		
Imidazoles	654	<b>SECTION SIX: GENERAL TOPICS</b>	
Tolnaftate; Griseofulvin	656		
<b>33: Antiprotozoal drugs</b>	<b>657</b>	<b>35: Non-therapeutic drugs: nicotine, alcohol and cannabis</b>	<b>677</b>
Malaria	657	Nicotine and tobacco	678
The life cycle of the malaria parasite	657	Alcohol	683
Antimalarial drugs	660	Cannabis	689
4-Aminoquinolines	660		
Drugs affecting the synthesis or utilization of folate	663	<b>36: Harmful effects of drugs</b>	<b>692</b>
Potential new antimalarial drugs	664	Types of drug toxicity	692
Amoebiasis	665	Hepatotoxicity	693
Metronidazole	665	Mutagenesis and carcinogenicity	695
Diloxanide; Chloroquine etc.	666	Tetratogenesis	698
Leishmaniasis	667	Allergic reactions to drugs	702
Trypanosomiasis	667	<b>Figure acknowledgement references</b>	<b>706</b>
Trichomoniasis	668	<b>Index</b>	<b>711</b>

# General principles



## Mechanisms of drug action

Pharmacology can be defined as the study of the manner in which the function of living systems is affected by chemical agents. It is a rather young science, having first achieved independent recognition at the end of the nineteenth century in Germany. Long before this, of course, medical remedies based on herbs were in widespread use, but there was a surprising reluctance to apply anything resembling scientific principles to therapeutics. Even Robert Boyle (1692), who laid the scientific foundations of chemistry in the middle of the seventeenth century, was content when dealing with therapeutics, to describe and recommend a hotchpotch of messes consisting of worms, dung, urine and the moss from a dead man's skull. It may be said, indeed, that therapeutics was scarcely influenced by science until the mid-nineteenth century, at which date Virchow dismissed the subject thus: 'Therapeutics is in an empirical stage cared for by practical doctors and clinicians, and it is by means of a combination with physiology that it must rise to be a science, which today it is not.' At that time the knowledge of the normal and abnormal functioning of the body were simply too incomplete to provide even a rough basis for understanding drug effects; at the same time there was a strong feeling that disease and death were semi-sacred subjects, appropriately dealt with by authoritarian, rather than scientific doctrines.

The history of malaria treatment shows how clinical practice could display an obedience to authority, and ignore what appear to be easily ascertainable facts. Cinchona bark was recognized as a specific and effective treatment, and a sound protocol for its use was laid down by Lind in 1765. In 1804, however, Johnson stated, on the basis of clinical practice in India, that cinchona bark was

unsafe until the fever had subsided, and recommended instead the use of large doses of calomel in the early stages. This advice, though murderous in practice, was generally acted upon for the next 40 years.

### SYSTEMS OF MEDICINE

Repeated attempts were made to construct systems of therapeutics, many of which produced even worse results than pure empiricism. One of these was **allopathy**, which was espoused by James Gregory (1735–1821). The favourite remedies were blood-letting, emetics and purgatives, and these were used until the dominant symptoms of the disease were suppressed. Many patients died from such treatment, and it was in reaction against it that Hahnemann introduced the practice of **homoeopathy** in the early nineteenth century. The guiding principles of homoeopathy are (a) that like cures like, and (b) that activity can be enhanced by dilution. The system rapidly drifted into absurdity: for example, Hahnemann recommended the use of drugs at dilutions of  $1:10^{60}$ , equivalent to one molecule in a sphere the size of the orbit of Neptune. Many other systems of therapeutics have come and gone, but the variety of dogmatic principles that they embodied has tended to hinder rather than advance scientific progress. Scientific understanding of drug action—the kind of understanding that enables us to predict what pharmacological effects a novel chemical substance is likely to produce, or to design a chemical that will produce a specified therapeutic effect—is still extremely patchy. To get to the root of how the intrusion of a particular chemical substance affects



the functioning of any given cell or organ obviously requires a detailed knowledge of the normal biochemical and physiological machinery, and it must be remembered that physiology only began to be studied intensively about 100 years ago, and biochemistry only about 50 years ago. Even so, from the plethora of experimental data on drug action amassed in the last 50 years or so, certain generalizations emerge, and these are discussed in this chapter.

To begin with we should gratefully acknowledge Paul Ehrlich (1913) for insisting that drug action should be understood in terms of conventional chemical interactions between drugs and tissues, and for dispelling the idea that the remarkable potency and specificity of action of some drugs put them somehow out of reach of chemistry and physics and required the intervention of magical 'vital forces'. Although it is the case that many drugs produce actions in doses and concentrations so small that the dimensions assume an almost astronomical remoteness, low concentrations still involve very large numbers of molecules. Thus one drop of a solution of a drug at only  $10^{-10}$  M still contains about  $10^{10}$  drug molecules, so there is no mystery in the fact that it may produce an obvious pharmacological response. Some bacterial toxins (e.g. diphtheria toxin) act with such precision that a single molecule taken up by a target cell is sufficient to kill it.

## THE BINDING OF DRUG MOLECULES TO CELLS

One of the basic tenets of pharmacology is that drug molecules must exert some chemical influence on one or more constituents of cells in order to produce a pharmacological response. In other words, drug molecules must approach the molecules of which cells are made sufficiently closely that the functioning of the cellular molecules is altered. Of course, the molecules in the organism vastly outnumber the drug molecules, and if the drug molecules were merely distributed at random, the chance of an interaction with any particular class of cellular molecule would be negligible. Pharmacological effects therefore require, in

general, the non-uniform distribution of the drug molecules within the body or tissue, which is the same as saying that drug molecules must be 'bound' to particular constituents of cells and tissues in order to produce an effect. Ehrlich summed it up thus: '*Corpora non agunt nisi fixata*', (In this context, 'A drug will not work unless it is bound'). A consideration of the different types of drug binding leads us to a useful general classification of drug action which is valid, even though for most drugs we have little or no information about the molecular details of the binding process.

To get an appreciation of the range of possibilities in the binding of drug molecules, let us consider examples at two extremes, namely **ethanol** and **histamine** (an endogenous amine released locally from damaged tissues) which are about as different as two drugs can be, in four general respects:

1. **Potency.** Most effects of histamine are produced in concentrations ranging from about  $10^{-8}$  to  $10^{-5}$  M, whereas ethanol is effective at concentrations ranging from about  $10^{-2}$  to  $10^{-1}$  M in body fluids. The legal limit for driving a car (80 mg/100 ml blood) corresponds to about 18 mM ethanol. On a molar basis, the difference in potency between ethanol and histamine is thus about five or six orders of magnitude. The high potency of histamine is by no means exceptional in pharmacology: drugs which act at concentrations of about  $10^{-9}$  M are quite common and there are reliable reports of effects produced at  $10^{-11}$ – $10^{-12}$  M (for example, the action of serotonin on mollusc hearts, and the action of peptides such as angiotensin on vascular smooth muscle).

2. **Biological specificity.** Histamine has a number of pharmacological actions, but it may produce opposite effects on apparently similar tissues, and it is without observable effects on many more. Thus it causes a powerful contraction of bronchial smooth muscle, but a relaxation of vascular smooth muscle, stimulating gastric secretion, but not salivary secretion. In contrast ethanol produces a more or less similar inhibitory effect on most cells and tissues. The physiological effects of alcohol may be highly complex but at a cellular level its actions are rather uniform, whereas those of histamine are highly selective, in the sense that its actions are confined to a few specific cell types.

3. **Chemical specificity.** Changes in the chemical